RCS - PayPoint PLC - PayPoint expands Randox partnership

PayPointAnnouncement

06/01/2022 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220106:nRSF6866Xa&default-theme=true

RNS Number : 6866X  PayPoint PLC  06 January 2022

 

PRESS RELEASE

PAYPOINT AND RANDOX PARTNER TO BOOST ACCESSIBILITY OF DAY 2 TESTING

The updated collaboration opens up PayPoint's extensive retail network to
offer increased convenience to travellers returning to the UK

6 January 2022, Welwyn Garden City: PayPoint and Randox have today announced
an expansion of their partnership, to boost access to COVID-19 testing and
provide a vital service to travellers returning to the UK, in line with the
Government's new arrival requirements for Day 2 testing, announced on
Wednesday 5(th) January.

The expanded partnership between PayPoint and Randox will mean even easier
access to low-cost COVID-19 testing, by enabling people to order a Randox test
online for click and collect at a local store within the Collect+ network,
initially available in over 5,000 locations, and soon in over 10,000 locations
nationwide.

The service launches on 7th January 2022 to coincide with changes to travel
policy which, from 4am on 9(th) January, allows fully vaccinated arrivals from
non-red list countries to take a lateral flow (antigen) test, with a PCR test
only required if a positive lateral flow result is returned.

In addition, from mid-January, PayPoint will give consumers the ability to
walk into a local store and pick up a test immediately in over 2,500
locations, with no need to order online. This service will be offered in
partnership with major convenience retailers including Scotmid Co-operative
and Spar in the North West and Scotland.

Dr Peter FitzGerald, Managing Director at Randox said: "By drawing on our 40
years' diagnostics experience, unparalleled testing capacity, and
well-established logistics network, which now includes an extensive number of
new locations from PayPoint, Randox is able to respond quickly to changing
travel requirements and simplify the process of ordering Day 2 lateral flow
tests.

"The availability of value for money tests that can be collected at the
customer's convenience thanks to our partnership with PayPoint means people in
the UK don't need to wait for home delivery or a walk-in clinic appointment
when ordering a COVID-19 test."

Nick Wiles, Chief Executive at PayPoint said: "Our expanded partnership with
Randox will deliver yet another vital service to help keep people safe in
communities across the UK.  Consumer convenience and accessibility are at the
very heart of what we do and this is another example of our agility,
responsiveness and the great relationships we have with our retailer partners
in the ever-changing landscape across the UK."

Day 2 lateral flow tests must be ordered before travel to England and can be
ordered from 4am on 7th January. Thanks to the updated collaboration between
PayPoint and Randox, people can now conveniently collect these tests from
local stores for just £18.95, rather than waiting at home for deliveries to
arrive.

Using the free Randox CertiFly App results are processed within 3 hours and a
report delivered in-app and via email, allowing arrivals into England to
complete their Day 2 test conveniently in the comfort of their own home, and
for individuals who test positive, potentially reducing the amount of time
they need to isolate.

-ENDS-

PayPoint Press
Office

MHP Communications

paypoint@mhpc.com

+44 20 3128 8100

Randox Press Office

Ian Monk

ian@ianmonk.com (mailto:ian@ianmonk.com)

+44 7970 026072 / + 44 203 011 1933

 

ABOUT PAYPOINT GROUP

For tens of thousands of businesses and millions of consumers, we deliver
innovative technology and services that make life a little easier.

The PayPoint Group serves a diverse range of organisations, from SME and
convenience retailer partners, to local authorities, multinational service
providers and e-commerce brands. Our products are split across three core
business divisions:

·    In Shopping, we enhance retailer propositions and customer
experiences through EPoS services via PayPoint One, card payment technology,
Counter Cash, ATMs and home delivery technology partnerships in over 60,000
SME and retailer partner locations across multiple sectors. Our retail network
of over 28,000 convenience stores is larger than all the banks, supermarkets
and Post Offices put together

·    In E-commerce, we deliver best-in-class customer journeys through
Collect+, a tech-based delivery solution that allows parcels to be sent,
picked up and dropped off at thousands of local stores

·    In Payments and Banking, we help companies and their customers make
and receive payments quickly and conveniently. This includes our digital
payments platform, MultiPay, an eMoney offering that enables cash through to
digital transactions and cash solutions providing vital consumer access across
our extensive retail network

Together, these solutions enable The PayPoint Group to create long-term value
for all stakeholders, including customers, communities and the world we live
in.

 

ABOUT RANDOX

Established in 1982, Randox is the largest healthcare diagnostics company from
the UK and Ireland; undertaking research, development, manufacture and
distribution of innovative laboratory tests and analysers.  In 2020 Randox
manufactured 4.2 billion tests and operated in 145 countries.  With over
2,000 staff, including 450 research scientists and engineers, key facilities
are located in Co Antrim, Co Donegal, London, Liverpool and Dublin.

 Randox focuses on the provision of timely and accurate testing in order to
identify risk to health, improve clinical diagnoses and promote preventative
healthcare; aiming to achieve better healthcare outcomes whilst reducing the
burden on clinical services. The company's comprehensive portfolio includes
tests for cardiovascular disease, diabetes, cancer, Alzheimer's disease and
stroke.

Randox's proprietary Biochip Technology allows many tests to be run
simultaneously, greatly improving the diagnostic power available to
clinicians.  This innovation enables Randox Health Clinics in Liverpool,
London and Northern Ireland to provide advanced health screening involving
hundreds of diagnostic tests.  Such health checks provide an extraordinary
insight into a person's current and future health.

 In early 2020 Randox recognised the threat from COVID-19 and, based on
almost 40 years of diagnostic experience, quickly developed a test to
accurately identify the virus.  Testing at scale commenced within weeks to
support the UK's National Testing Programme and private clients.

Through the enormous effort and commitment of its staff Randox is subsequently
operating at a capacity of 180,000 COVID-19 samples per day, making it amongst
the very largest COVID-19 laboratories in the UK and Europe. Randox has
surpassed 23 million gold-standard PCR tests for the National Testing
Programme and private COVID testing for travel.

Randox is clear that better diagnostics are unquestionably critical to future
improvements within healthcare and is committed to remaining at the forefront
of that field.

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAZZGGMDVFGZZM